talniflumate

Talniflumate is an orally available small molecule prodrug of niflumic acid, classified as a nonsteroidal anti-inflammatory drug (NSAID). It exhibits potent analgesic and anti-inflammatory effects and has been used primarily for the treatment of inflammatory disorders such as rheumatoid arthritis and osteoarthritis. Talniflumate also acts as a mucin regulator, studied in cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, and certain gastrointestinal disorders. Its mechanism involves selective inhibition of the core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase), leading to decreased mucin production. Additionally, it blocks prostaglandin synthesis by inhibiting cyclooxygenases and acts as a strong calcium-activated chloride channel blocker. Talniflumate was originally developed by Laboratorios Bago and later pursued by Genaera[1][2][3][9].

Brand names

LOMUCIN

Other names

talniflumate2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester